Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPDGF-BB Gel for Second-Degree Burn Wound Healing (Phase IIb, China)
ChiCTR2300078312Phase 2Recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of becaplermin in burn injury (6 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Time for complete healing. Started Nov 2023; status: recruiting.
02
Drugs
becaplermin
03
Conditions
burn injury
Beyond the preview
Go deeper on ChiCTR2300078312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078312.